AU2012257736B2 - A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII - Google Patents

A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII Download PDF

Info

Publication number
AU2012257736B2
AU2012257736B2 AU2012257736A AU2012257736A AU2012257736B2 AU 2012257736 B2 AU2012257736 B2 AU 2012257736B2 AU 2012257736 A AU2012257736 A AU 2012257736A AU 2012257736 A AU2012257736 A AU 2012257736A AU 2012257736 B2 AU2012257736 B2 AU 2012257736B2
Authority
AU
Australia
Prior art keywords
cell suspension
cell
cells
rfviii
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012257736A
Other languages
English (en)
Other versions
AU2012257736A1 (en
Inventor
Irene Agerkvist
Peter Aizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45470754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012257736(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma AG filed Critical Octapharma AG
Publication of AU2012257736A1 publication Critical patent/AU2012257736A1/en
Application granted granted Critical
Publication of AU2012257736B2 publication Critical patent/AU2012257736B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/42—Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2012257736A 2011-05-13 2012-05-14 A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII Active AU2012257736B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11166071 2011-05-13
EP11166071.8 2011-05-13
US201161489406P 2011-05-24 2011-05-24
US61/489,406 2011-05-24
PCT/EP2012/058899 WO2012156356A1 (en) 2011-05-13 2012-05-14 A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii

Publications (2)

Publication Number Publication Date
AU2012257736A1 AU2012257736A1 (en) 2013-10-10
AU2012257736B2 true AU2012257736B2 (en) 2015-12-10

Family

ID=45470754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012257736A Active AU2012257736B2 (en) 2011-05-13 2012-05-14 A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII

Country Status (13)

Country Link
US (1) US9115381B2 (cg-RX-API-DMAC7.html)
EP (3) EP4353743A3 (cg-RX-API-DMAC7.html)
JP (1) JP6178786B2 (cg-RX-API-DMAC7.html)
KR (1) KR101980164B1 (cg-RX-API-DMAC7.html)
CN (1) CN103517919B (cg-RX-API-DMAC7.html)
AU (1) AU2012257736B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013028006A2 (cg-RX-API-DMAC7.html)
CA (1) CA2835053C (cg-RX-API-DMAC7.html)
DK (1) DK3626737T3 (cg-RX-API-DMAC7.html)
ES (1) ES2970057T3 (cg-RX-API-DMAC7.html)
IL (1) IL229058A (cg-RX-API-DMAC7.html)
RU (1) RU2600886C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012156356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6591609B2 (en) 1997-07-15 2003-07-15 New Power Concepts Llc Regenerator for a Stirling Engine
US11384378B2 (en) 2014-06-04 2022-07-12 Amgen Inc. Methods for harvesting mammalian cell cultures
CN107287265B (zh) * 2016-03-31 2018-09-14 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
JP2025520392A (ja) * 2022-06-15 2025-07-03 ユーシービー バイオファルマ エスアールエル 細胞培養プロセス
CN120005720B (zh) * 2025-04-21 2025-08-08 深圳市茵冠生物科技有限公司 一种人工智能的细胞培养监测方法及系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AU780415B2 (en) * 1999-07-13 2005-03-17 Biovitrum Ab Stable Factor VIII compositions
EP1266006B1 (en) 2000-03-22 2005-12-07 Octagene GmbH Production of recombinant muteins of blood clotting factor viii in human cell lines
EP1720972B1 (en) * 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
JP2006296423A (ja) * 2005-03-24 2006-11-02 Hitachi Ltd 培養槽の制御装置及び培養装置
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
WO2006103298A2 (en) * 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
PL2343362T5 (pl) 2006-07-14 2024-12-02 Patheon Holdings I B.V. Ulepszony proces hodowli komórek
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
JPWO2009090787A1 (ja) * 2008-01-15 2011-05-26 東レ株式会社 生理活性ペプチドまたはタンパク質製造方法、および組換え動物細胞
AU2009264282B2 (en) * 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
DE102008049120A1 (de) 2008-09-26 2010-04-01 Bayer Technology Services Gmbh Verfahren zur Reduzierung von Ablagerungen bei der Kultivierung von Organismen
EP2216395A1 (en) 2009-02-09 2010-08-11 Lonza Biologics plc. Bioreactor for the cultivation of mammalian cells
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture

Also Published As

Publication number Publication date
CA2835053C (en) 2020-07-07
CN103517919B (zh) 2016-11-16
KR101980164B1 (ko) 2019-05-20
JP6178786B2 (ja) 2017-08-09
JP2014513545A (ja) 2014-06-05
CA2835053A1 (en) 2012-11-22
AU2012257736A1 (en) 2013-10-10
US9115381B2 (en) 2015-08-25
EP4353743A3 (en) 2024-07-17
US20140051123A1 (en) 2014-02-20
BR112013028006A2 (pt) 2016-09-06
EP2707387B1 (en) 2019-12-25
IL229058A (en) 2017-03-30
WO2012156356A1 (en) 2012-11-22
RU2600886C2 (ru) 2016-10-27
EP3626737B1 (en) 2023-11-29
IL229058A0 (en) 2013-12-31
EP3626737A1 (en) 2020-03-25
EP4353743A2 (en) 2024-04-17
EP2707387A1 (en) 2014-03-19
RU2013155382A (ru) 2015-06-20
CN103517919A (zh) 2014-01-15
DK3626737T3 (da) 2024-02-05
KR20140021009A (ko) 2014-02-19
ES2970057T3 (es) 2024-05-24

Similar Documents

Publication Publication Date Title
AU2012257736B2 (en) A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
Karst et al. Characterization and comparison of ATF and TFF in stirred bioreactors for continuous mammalian cell culture processes
US20240247218A1 (en) Large scale pei-mediated plasmid transfection
Birch et al. Suspension culture of mammalian cells
US8440800B2 (en) Compositions for reducing cell adhesion to bubbles
EA022219B1 (ru) Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре
Nienow et al. Bioreactor engineering fundamentals for stem cell manufacturing
US20200165557A1 (en) Large-Scale PEI-Mediated Plasmid Transfection
WO1986007604A1 (en) Fermenter
JP2017511144A (ja) 高細胞密度フィル・アンド・ドロー発酵プロセス
CN114901794A (zh) 用于生产接种物的过程和系统
Murasiewicz et al. Engineering considerations on the use of liquid/liquid two‐phase systems as a cell culture platform
Kuystermans et al. Bioreactor systems for producing antibody from mammalian cells
ES2777173T3 (es) Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
Nilsson et al. [35] Entrapment of animal cells
Ahmed Application of hydrocyclone for cell separation in mammalian cell perfusion cultures
Chalmers The challenges of hydrodynamic forces on cells used in cell manufacturing and therapy
JPH05284966A (ja) 通気撹拌二段階培養法
EP4574969A1 (en) A method of producing differentiated cells from pluripotent stem cells, cell populations obtained by the method, corresponding pharmaceutical compositions and a system for producing differentiated cells from pluripotent stem cells
Ryan Growing more cells: A simple guide to small volume cell culture scale-up
US20210214702A1 (en) Process for production of recombinant tnk-tpa by packed-bed perfusion system
Halsall et al. Systems for cell culture scale-up
RU2295571C2 (ru) Способ получения препаративных количеств плазмидной днк из клеток рекомбинантных микроорганизмов
ARATHOON JOHN R. BIRCH
Griffiths Scaling-up of animal cell

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)